外科肿瘤学研讨会 - 胰腺癌辅助治疗试验

Seminars in surgical oncology-Pancreas cancer adjuvant therapy trials.

作者信息

Essaji Yasmin, Rocha Flavio G

机构信息

Section of General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, Washington, USA.

Division of Surgical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.

出版信息

J Surg Oncol. 2021 May;123(6):1467-1474. doi: 10.1002/jso.26382.

DOI:10.1002/jso.26382

PMID:33831255

Abstract

Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.

摘要

在过去30年中，胰腺癌的辅助治疗经历了范式转变。20世纪90年代以前，手术是主要治疗方法，发病率高且长期生存率极低。20世纪80年代中期，胃肠道肿瘤研究组（GITSG）显示，基于5-氟尿嘧啶的放化疗可使总生存期从11个月翻倍至20个月，而现在的PRODIGE试验显示了FOLFIRINOX方案的益处，目前最长总生存期接近5年。关于治疗药物、疗程和顺序的进一步研究仍在进行中。